IDEAYA Biosciences, Inc. Common Stock
Symbol: IDYA (NASDAQ)
Company Description:
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Today's Open: $24.71
- Today's High: $25.305
- Today's Low: $24.38
- Today's Volume: 1.46M
- Yesterday Close: $24.74
- Yesterday High: $25.09
- Yesterday Low: $23.5255
- Yesterday Volume: 2.16M
- Last Min Volume: 2
- Last Min High: $25.01
- Last Min Low: $25.01
- Last Min VWAP: $25.01
- Name: IDEAYA Biosciences, Inc. Common Stock
- Website: https://www.ideayabio.com
- Listed Date: 2019-05-23
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001676725
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $2.05B
- Round Lot: 100
- Outstanding Shares: 87.64M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-08 | 8-K | View |
2025-09-02 | 8-K | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-13 | SCHEDULE 13G | View |
2025-08-05 | S-8 | View |
2025-08-05 | 10-Q | View |
2025-08-05 | 8-K | View |
2025-06-27 | 3 | View |
2025-06-27 | 8-K | View |
2025-06-26 | 4 | View |
2025-06-26 | 4 | View |
2025-06-26 | 4 | View |
2025-06-26 | 4 | View |
2025-06-26 | 4 | View |
2025-06-26 | 4 | View |
2025-06-24 | 8-K | View |
2025-06-09 | SCHEDULE 13G | View |
2025-05-20 | ARS | View |
2025-05-14 | SCHEDULE 13G/A | View |
2025-05-06 | 10-Q | View |